The Dermatology Drug Development Summit series is a unique industry-focused forum dedicated to innovating, accelerating and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs, in the treatment of high unmet need.
The dermatology space continues to undergo huge therapeutic innovation and growing competitive pressure, driven by the evolving understanding of the pathophysiology of skin diseases, as well as in the available treatment options for chronic, moderate to severe dermatological conditions and high unmet need that affects the lives of patients worldwide.
The 3rd Annual Dermatology Drug Development Summit provides leading industry experts with a unique forum to debate the end-to-end challenges in dermatology drug development: from discovering new research on key disease pathways, to unveiling critical preclinical insights, discussing formulation strategies, defining the optimal clinical development plans or evaluating commercialization approaches.
Join peers and leaders in this space for an exclusive three-day meeting of comprehensive discussion, sharing of latest advances and pioneering insights, and networking opportunities.
Early booking and group discounts apply, start-up and academic rates are available - see the website for details.
Standard Rate - Conference and 3 Workshops: USD 4696.0
Standard Rate - Conference and 2 Workshops: USD 4097.0
Standard Rate - Conference and 1 Workshop: USD 3498.0
Standard Rate - Conference Only: USD 2899.0
Standard Rate - Workshop Only: USD 699.0
Start-up/Academic Rate - Conference and 3 Workshops: USD 2796.0
Start-up/Academic Rate - Conference and 2 Workshops: USD 2497.0
Start-up/Academic Rate - Conference and 1 Workshop: USD 2198.0
Start-up/Academic Rate - Conference Only: USD 1899.0
Start-up/Academic Rate - Workshop Only: USD 399.0
Speakers: Adam Raff, Director, Translational Medicine, LEO Pharma, Alon Mantel, Skin Biology, Tergus Pharma, Angela Christiano, Professor and Vice Chair for Research, Department of Dermatology, Columbia University, Betsy Hughes-Formella, Independent Consultant, Dermatological Drug Development , Brett King, Associate Professor of Dermatology, Yale University School of Medicine, Dan Piacquadio, CEO, Therapeutics Inc., David Rubenstein, CSO, Dermavant Sciences, Dirk Brockstedt, CSO, RAPT Therapeutics, Elena Rizova, VP and Head of Global Medical Affairs, Immuno Inflammation, Sanofi, Frank Sinner, Director, Institute for Biomedicine and Health Sciences, Joanneum Research, Gurpreet Ahluwalia, Executive Director, Clinical Development, Sienna Biopharmaceuticals, Jasmina Jankicevic, Dermatologist, Clinical Development and Medical Affairs Consulting , John Armstrong, Head of Global Strategic Opportunities, Galderma, John Harris, Vice Chair of Dermatology and Director, Vitiligo Clinic and Research Center, University of Massachusetts Medical School, Jon Lenn, CTO, Medpharm, Ken Cacciatore, Managing Director, Health Care - Pharmaceuticals/Specialty, Cowen, Kendall Marcus, Director - Division of Dermatology and Dental Products, FDA, Mandeep Kaur, VP and Head of North America Medical Affairs for Immunology, Sanofi, Michael Howell, Senior Director – Translational Research, Incyte Corporation , Michael Kuligowski, Executive Medical Director - Inflammation and Autoimmunity, Incyte Corporation, Ofer Toledano, VP, RandD, Sol-Gel Technologies, Paul F. Lizzul, CMO, Sienna Biopharmaceuticals, Paul Smith, Senior Director - Preclinical Pharmacology, Incyte Corporation, Rajiv Mathur, VP, Product Development, CPL, Robert Rissmann, Research Director, Dermatology, Center for Human Drug Research (CDHR), Sean Andrews, VP, Investor Relationships, Sienna Biopharmaceuticals, Sonya Abraham, Head of New Treatment Strategies, Immune-Dermatology, UCB, Suma Krishnan, Founder and COO, Krystal Biotech, Tammy Payne, Analytical RandD, Tergus Pharma, Vijendra Nalamothu, Chairman and CEO, Tergus Pharma, Wendy Smith, Begolka Director, Research, National Eczema Association (NEA)
Time: 8:45 am - 3:00 pm